Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus: evaluation report
Consultee and commentator comments on the first ACD
External expert comments on the appraisal consultation document
Report to the Appraisal Committee summarising comments (received by letter and email) on the appraisal consultation document - prepared by the Patient and Public Involvement Programme (PPIP) and Enquiry Handling team, September 2008
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic and economic evaluation - addendum to the report submitted on 2 May 2008 - prepared by Peninsula Technology Assessment Group (PenTAG), University of Exeter
Extra work on bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma - prepared by Decision Support Unit
First appraisal consultation document
Response from the Assessment Group to comments on the Assessment report
Consultee and commentator comments on the extra work consultation
Extra work done by the Assessment Group (PenTAG) and the Decision Support Unit (DSU) on new data received
External expert comments received on the extra work consultation
Response from the DSU to comments on the extra work consultation
Revised analyses submitted by Bayer incorporating the sorafenib patient access scheme and new price of sorafenib
Extra work done by the DSU on the revised analyses submitted by Bayer
Department of Health approval for the Technology Appraisal Committee to consider patient access schemes submitted for sorafenib and sunitinib
Consultee and commentator comments on the executable economic model
DSU addendum to the review of Roche's request for parameter changes
Addendum to the pre-meeting briefing: end of life - a quantitative exploration
This page was last updated: 30 March 2010